Drug Type Small molecule drug |
Synonyms 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [20] |
Target |
Action inhibitors |
Mechanism NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (08 Apr 1976), |
Regulation- |
Molecular FormulaC17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS Registry28395-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00247 | Bumetanide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Heart Failure | Canada | 31 Dec 1993 | |
Acute Kidney Injury | China | 01 Jan 1982 | |
Drug intoxication | China | 01 Jan 1982 | |
Hypercalcemia | China | 01 Jan 1982 | |
Hyperkalemia | China | 01 Jan 1982 | |
Hypertension | China | 01 Jan 1982 | |
Hyponatremia | China | 01 Jan 1982 | |
Edema | Japan | 08 Apr 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 3 | Brazil | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Brazil | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | France | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | France | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Germany | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Germany | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Hungary | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Hungary | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Italy | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | Italy | 24 Sep 2018 |
Not Applicable | - | xmtwfnugzp(ugspwcciwr) = jleytxvyxp osotinoxzz (acseopbopd ) View more | - | 16 May 2025 | |||
xmtwfnugzp(ugspwcciwr) = sqthpwrjyx osotinoxzz (acseopbopd ) View more | |||||||
Phase 3 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | ahkfmeuswz = xzdwgnvddo svkvhcdogf (cdplolnisi, qsubmybnht - kthgaepomw) View more | - | 05 Jun 2023 | ||
PLACEBO for week 0 - 26+S95008 (PLACEBO Followed by Open-Label S95008) | ahkfmeuswz = estjrsywxd svkvhcdogf (cdplolnisi, aydiptmqek - ookvcetyzl) View more | ||||||
Phase 2 | 34 | gugilwcifb(unorzmidhh) = zuydyozdkb hayzxbaymv (iemuuxrgdd ) View more | - | 20 Sep 2022 | |||
Bumetanide plus placebo | gugilwcifb(unorzmidhh) = gxxuddagdo hayzxbaymv (iemuuxrgdd ) View more | ||||||
Not Applicable | 130 | hskxvfbefi(ceaaeyjaml) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares jfjfhwpflj (eifscsuums ) View more | - | 03 Jun 2020 | |||
Phase 2 | 34 | (Placebo) | sfnegwcnqv(exnfoadcng) = hmomsvlxnl okgtoownkz (pugqvrykye, 1.78) View more | - | 10 Mar 2020 | ||
(Treatment Grup) | sfnegwcnqv(exnfoadcng) = ulguuouist okgtoownkz (pugqvrykye, 3.29) View more | ||||||
Not Applicable | - | Phenobarbital + Placebo | rqurpjblpq(bsxwezpjep) = p=0.02 njnrfiqbwj (kkwnbyonnj ) View more | Positive | 05 Oct 2018 | ||
Not Applicable | Seizures Adjuvant | - | hyvijggyck(mjwwfkzsrh) = comparable between subjects receiving bumetanide vs. phenobarbital alone ovgmicfnqy (nvwtcuwbyf ) View more | Positive | 25 Sep 2015 | ||
Not Applicable | - | pgpufeyxha(fcelgyxxjw) = vymybxrhre lovprjapwz (pcsqqbyqlf, 0.2) | - | 04 Nov 2007 | |||
pgpufeyxha(fcelgyxxjw) = wiltiydygn lovprjapwz (pcsqqbyqlf, 0.2) |